1
|
Bray JA, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Matsuoka T and Yashiro M: Rho/ROCK
signaling in motility and metastasis of gastric cancer. World J
Gastroenterol. 20:13756–13766. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kang YK, Kang WK, Shin DB, Chen J, Xiong
J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, et al:
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in patients with advanced gastric cancer: A
randomised phase III noninferiority trial. Ann Oncol. 20:666–673.
2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yuan DD, Zhu ZX, Zhang X and Liu J:
Targeted therapy for gastric cancer: Current status and future
directions (Review). Oncol Rep. 35:1245–1254. 2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
O'Neill GM, Fashena SJ and Golemis EA:
Integrin signalling: A new Cas(t) of characters enters the stage.
Trends Cell Biol. 10:111–119. 2000. View Article : Google Scholar : PubMed/NCBI
|
7
|
Law SF, Estojak J, Wang B, Mysliwiec T,
Kruh G and Golemis EA: Human enhancer of filamentation 1, a novel
p130cas-like docking protein, associates with focal adhesion kinase
and induces pseudohyphal growth in saccharomyces cerevisiae. Mol
Cell Biol. 16:3327–3337. 1996. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kim M, Gans JD, Nogueira C, Wang A, Paik
JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, et al:
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis
gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhang Q, Wang H, Ma Y, Zhang J, He X, Ma J
and Zhao ZS: Overexpression of Nedd9 is a prognostic marker of
human gastric cancer. Med Oncol. 31:332014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang L, Shi G, Zhu D, Jin Y and Yang X:
miR-5195-3p suppresses cell proliferation and induces apoptosis by
directly targeting NEDD9 in osteosarcoma. Cancer Biother
Radiopharm. 34:405–412. 2019. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lu R, Ji Z, Li X, Zhai Q, Zhao C, Jiang Z,
Zhang S, Nie L and Yu Z: miR-145 functions as tumor suppressor and
targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J
Cancer Res Clin Oncol. 140:387–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Xue Y, Wu T, Sheng Y, Zhong Y, Hu B and
Bao C: MicroRNA-1252-5p, regulated by Myb, inhibits invasion and
epithelial-mesenchymal transition of pancreatic cancer cells by
targeting NEDD9. Aging (Albany NY). 13:18924–18945. 2021.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Shi R, Wang L, Wang T, Xu J, Wang F and Xu
M: NEDD9 overexpression correlates with the progression and
prognosis in gastric carcinoma. Med Oncol. 31:8522014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang S, Wu L, Liu Q, Chen K and Zhang X:
Study on effect of the expression of siRNA in gastric cancer
bearing nude mice transplanted tumor NEDD9 gene. Pak J Pharm Sci.
27 (5 Suppl):S1651–S1656. 2014.
|
19
|
Zhang S, Wu L, Liu Q, Chen K and Zhang X:
Impact on growth and invasion of gastric cancer cell lines by
silencing NEDD9. Onco Targets Ther. 8:223–231. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhao S, Min P, Liu L, Zhang L, Zhang Y,
Wang Y, Zhao X, Ma Y, Xie H, Zhu C, et al: NEDD9 facilitates
hypoxia-induced gastric cancer cell migration via MICAL1 related
Rac1 activation. Front Pharmacol. 10:2912019. View Article : Google Scholar : PubMed/NCBI
|
21
|
Elaidy NF, Harb OA, Mohamed AM, Hemeda R,
Taha HF, Samir A, Elsayed AM, Osman G and Hendawy EIE: Prognostic
significances of NEDD-9 and FOXL-1 expression in intestinal type
gastric carcinoma: An immunohistochemical study. J Gastrointest
Cancer. 52:728–737. 2021. View Article : Google Scholar : PubMed/NCBI
|
22
|
Lerotić I, Vuković P, Hrabar D, Misir Z,
Kruljac I, Pavić T, Forgač J, Ćaćić P and Ulamec M: Expression of
NEDD9 and connexin-43 in neoplastic and stromal cells of gastric
adenocarcinoma. Bosn J Basic Med Sci. 21:542–548. 2021.PubMed/NCBI
|
23
|
Wang D, Han X, Li C and Bai W: FBXL3 is
regulated by miRNA-4735-3p and suppresses cell proliferation and
migration in non-small cell lung cancer. Pathol Res Pract.
215:358–365. 2019. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhou W, Huang S, Jiang Q and Yuan T:
Suppression of miR-4735-3p in androgen receptor-expressing prostate
cancer cells increases cell death during chemotherapy. Am J Transl
Res. 9:3714–3722. 2017.PubMed/NCBI
|
25
|
Teng J, Ai X, Jia Z, Wang K, Guan Y and
Guo Y: Long non-coding RNA ARAP1-AS1 promotes the progression of
bladder cancer by regulating miR-4735-3p/NOTCH2 axis. Cancer Biol
Ther. 20:552–561. 2019. View Article : Google Scholar : PubMed/NCBI
|
26
|
Li C, Dong B, Xu X, Li Y, Wang Y and Li X:
LncRNA ARAP1-AS1 aggravates the malignant phenotypes of ovarian
cancer cells through sponging miR-4735-3p to enhance PLAGL2
expression. Cytotechnology. 73:363–372. 2021. View Article : Google Scholar : PubMed/NCBI
|
27
|
Li L and Li H: Role of microRNA-mediated
MMP regulation in the treatment and diagnosis of malignant tumors.
Cancer Biol Ther. 14:796–805. 2013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Ren F, Tang R, Zhang X, Madushi WM, Luo D,
Dang Y, Li Z, Wei K and Chen G: Overexpression of MMP family
members functions as prognostic biomarker for breast cancer
patients: A systematic review and meta-analysis. PLoS One.
10:e01355442015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Fioruci-Fontanelli BA, Chuffa LG, Mendes
LO, Pinheiro PF, Delella FK, Kurokawa CS, Felisbino SL and Martinez
FE: MMP-2 and MMP-9 activities and TIMP-1 and TIMP-2 expression in
the prostatic tissue of two ethanol-preferring rat models. Anal
Cell Pathol (Amst). 2015:9545482015.PubMed/NCBI
|
30
|
Mareel M, Bracke M, Van Roy F and Vakaet
L: Expression of E-cadherin in embryogenetic ingression and cancer
invasion. Int J Dev Biol. 37:227–235. 1993.PubMed/NCBI
|
31
|
Grauzam S, Brock AM, Holmes CO, Tiedeken
JA, Boniface SG, Pierson BN, Patterson DG, Coaxum SD, Neskey DM and
Rosenzweig SA: NEDD9 stimulated MMP9 secretion is required for
invadopodia formation in oral squamous cell carcinoma. Oncotarget.
9:25503–25516. 2018. View Article : Google Scholar : PubMed/NCBI
|
32
|
Meng H, Wu J, Huang Q, Yang X, Yang K, Qiu
Y, Ren J, Shen R and Qi H: NEDD9 promotes invasion and migration of
colorectal cancer cell line HCT116 via JNK/EMT. Oncol Lett.
18:4022–4029. 2019.PubMed/NCBI
|